Fosun Pharma divests stake in Amcare, advances new drug

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) is streamlining its portfolio by divesting its stake in Amcare, while simultaneously advancing its pharmaceutical pipeline. A subsidiary, Fosun Industrial, will sell its 6.6% stake in Amcare, equivalent to 9.4 million shares to Calcite Gem for $124.08 million, and the group will no longer hold any equity stake in Amcare.